A Phase 1 interventional study of Aprepitant and Ondansetron in Postoperative Nausea and Vomiting, sponsored by Merck Sharp & Dohme LLC. Completed at 6 sites in 5 countries. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2021-01-26.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing aprepitant in Postoperative Nausea and Vomiting — 2 open to participants now, 2 under way, none of them phase 3. Aprepitant · Postoperative Nausea and Vomiting.
Among the 27 studies testing aprepitant in Postoperative Nausea and Vomiting, this one is the 18th largest by enrollment, is the only one that started in 2009, is one of 2 in phase 1, and was the 6th registered.
638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.
Browse Postoperative Nausea and Vomiting studies →2 of the 27 studies testing aprepitant in Postoperative Nausea and Vomiting are open now, in 2 countries. Recruiting first, the newest first:
IWK Health Centre · Sites in Canada
Ages 8–19
Endeavor Health · Sites in United States
Ages 18–90
By country, each count listing its studies:
Aprepitant: first FDA approval 2003 (EMEND), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 65 Postoperative Nausea and Vomiting studies recruiting now, 22 (34%) set no upper age limit and 37 (57%) stop at 75 or younger; 14 take children under 18; 11 take healthy volunteers.
This study: 6 Months to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 4 · Phase 4 14
First in 2005; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is below the median of 112 across 529 interventional studies indexed under Postoperative Nausea and Vomiting.
Median enrollment 115 across the 27 interventional studies. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 5 studies filed under Postoperative Nausea and Vomiting — fewer than ten, so there is no comparison to draw.
2 of the studies testing aprepitant in Postoperative Nausea and Vomiting that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06357234IWK Health CentreAprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery | 2027-03 |
| NCT07639723Endeavor HealthAprepitant to Improve Same Day Discharge for TKA | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies testing aprepitant in Postoperative Nausea and Vomiting, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This two part study will determine the appropriate dosing regimen of aprepitant for the prevention of postoperative nausea and vomiting (PONV) in pediatric participants 6 months to 17 years of age, by assessing pharmacokinetic parameters and monitoring safety and tolerability of administered doses. Part I will be an open label investigation of a single dose of aprepitant measuring pharmacokinetics at specified time points up to 48 hours after aprepitant dosing. Part II will be a double blind trial of participants randomized to receive either aprepitant or ondansetron.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Study Part 1, participants aged 6 months to 17 years received a single oral dose of aprepitant on Day 1.
Drug: Aprepitant
In Study Part 2, participants aged 6 months to 17 years received a single oral dose of aprepitant on Day 1.
Drug: Aprepitant
In Study Part 2, participants aged 6 months to 17 years received a single intravenous dose of ondansetron on Day 1.
Drug: Ondansetron
Aprepitant administered orally or intraveously.
Also known as: Emend
Ondansetron administered intravenously.
Also known as: Zofran
Area Under the Curve From 0-48 (AUC0-48) of Aprepitant Following a Single Oral Dose in Study Part 1
Blood samples of 0.5 mL were collected from participants for the analysis of AUC0-48 at specified time points: pre-dose, and 1, 2, 3, 4, 8, 12, 24, and 48 hours post aprepitant single dose.
Time frame: Pre-dose, and 1, 2, 3, 4, 8, 12, 24, and 48 hours post-dose
Maximum Plasma Concentration (Cmax) of Aprepitant Following a Single Oral Dose in Study Part 1
Blood samples were collected from participants for the analysis of Cmax up to 48 hours after dosing.
Time frame: 48 Hours Post-Dose
Time to Maximum Plasma Concentration (Tmax) of Aprepitant Following a Single Oral Dose in Study Part 1
Blood samples were collected from participants for the analysis of Tmax up to 48 hours after dosing.
Time frame: 48 Hours Post-Dose
Plasma Concentration of Aprepitant at 24 Hours (C24 hr) Following a Single Oral Dose in Study Part 1
Blood samples were collected from participants for the analysis of C24 hr at 24 hours after dosing. N/A indicates that \>50% of measurements were below the lower level of quantitaion (LLOQ).
Time frame: 24 Hours Post-Dose
Plasma Concentration of Aprepitant at 48 Hours (C48 hr) Following a Single Oral Dose in Study Part 1
The mean plasma concentration of aprepitant was evaluated in participants at 48 hours following a single oral dose.
Time frame: 48 Hours Post-Dose
Number of Participants Experiencing Adverse Events (AEs)
Time frame: Up to 21 Days Post-Surgery
Number of Participants Discontinuing Study Treatment Due to AEs
Time frame: Day 1
Number of Participants With No Vomiting Up to 24 Hours Following Surgery in Study Part 2
Time frame: Up to 24 Hours
Number of Participants With Complete Response Up to 24 Hours Following Surgery in Study Part 2
Complete response was defined as no vomiting and no use of rescue medication in 0-24 hours post-surgery.
Time frame: Up to 24 Hours
Number of Participants With No Vomiting Up to 48 Hours Following Surgery Ini Study Part 2
Time frame: Up to 48 Hours
Number of Participants With Complete Response Up to 48 Hours Following Surgery in Study Part 2
Complete response was defined as no vomiting and no use of rescue medication in 0-48 hours post-surgery.
Time frame: Up to 48 Hours
Number of Participants With Vomiting Frequency in Study Part 2
Time frame: Up to 24 Hours
This trial was conducted at 18 trial centers: 2 in Brazil, 1 in Finland, 1 in Russia, 1 in Mexico, 4 in Spain, 6 in Turkey, and 3 in the United States.
| Milestone | Part 1: Oral Aprepitant | Part 2: Oral Aprepitant | Part 2: Intravenous Ondansetron |
|---|---|---|---|
| Started | 46 | 27 | 25 |
| Completed | 44 | 27 | 24 |
| Not completed | 2 | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
Blood samples of 0.5 mL were collected from participants for the analysis of AUC0-48 at specified time points: pre-dose, and 1, 2, 3, 4, 8, 12, 24, and 48 hours post aprepitant single dose.
| hr*ug/ml | Part 1: Oral Aprepitant |
|---|---|
| 6 months to <2 years (n=11) | 5.97 ± 4.44 |
| 2 years to <6 years (n=11) | 4.76 ± 3.55 |
| 6 years to <12 years (n=11) | 6.16 ± 2.27 |
| 12 years to 17 years (n=10) | 6.01 ± 2.53 |
Blood samples were collected from participants for the analysis of Cmax up to 48 hours after dosing.
| ng/mL | Part 1: Oral Aprepitant |
|---|---|
| 6 months to <2 years (n=11) | 715 ± 445 |
| 2 years to <6 years (n=11) | 586 ± 462 |
| 6 years to <12 years (n=11) | 913 ± 294 |
| 12 years to 17 years (n=10) | 520 ± 230 |
Blood samples were collected from participants for the analysis of Tmax up to 48 hours after dosing.
| Hours | Part 1: Oral Aprepitant |
|---|---|
| 6 months to <2 years (n=11) | 3.00 (1.00 to 8.00) |
| 2 years to <6 years (n=11) | 3.00 (1.03 to 12.00) |
| 6 years to <12 years (n=11) | 2.00 (1.00 to 8.00) |
| 12 years to 17 years (n=10) | 3.50 (1.00 to 11.98) |
Blood samples were collected from participants for the analysis of C24 hr at 24 hours after dosing. N/A indicates that \>50% of measurements were below the lower level of quantitaion (LLOQ).
| ng/mL | Part 1: Oral Aprepitant |
|---|---|
| 6 months to <2 years (n=11) | 31.0 ± 39.5 |
| 2 years to <6 years (n=11) | 58.6 ± 54.3 |
| 6 years to <12 years (n=11) | 51.1 ± 35.6 |
| 12 years to 17 years (n=10) | 81.1 ± 59.8 |
The mean plasma concentration of aprepitant was evaluated in participants at 48 hours following a single oral dose.
| ng/mL | Part 1: Oral Aprepitant |
|---|---|
| 6 months to <2 years (n=11) | NA ± NA |
| 2 years to <6 years (n=11) | NA ± NA |
| 6 years to <12 years (n=11) | NA ± NA |
| 12 years to 17 years (n=10) | 7.25 ± 8.90 |
| Participants | Part 1: Oral Aprepitant | Part 2: Oral Aprepitant | Part 2: Intravenous Ondansetron |
|---|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) | 20 | 12 | 7 |
| Participants | Part 1: Oral Aprepitant | Part 2: Oral Aprepitant | Part 2: Intravenous Ondansetron |
|---|---|---|---|
| Number of Participants Discontinuing Study Treatment Due to AEs | 0 | 0 | 0 |
| Participants | Part 2: Oral Aprepitant | Part 2: Intravenous Ondansetron |
|---|---|---|
| Number of Participants With No Vomiting Up to 24 Hours Following Surgery in Study Part 2 | 20 | 20 |
Complete response was defined as no vomiting and no use of rescue medication in 0-24 hours post-surgery.
| Participants | Part 2: Oral Aprepitant | Part 2: Intravenous Ondansetron |
|---|---|---|
| Number of Participants With Complete Response Up to 24 Hours Following Surgery in Study Part 2 | 19 | 20 |
| Participants | Part 2: Oral Aprepitant | Part 2: Intravenous Ondansetron |
|---|---|---|
| Number of Participants With No Vomiting Up to 48 Hours Following Surgery Ini Study Part 2 | 18 | 20 |
Complete response was defined as no vomiting and no use of rescue medication in 0-48 hours post-surgery.
| Participants | Part 2: Oral Aprepitant | Part 2: Intravenous Ondansetron |
|---|---|---|
| Number of Participants With Complete Response Up to 48 Hours Following Surgery in Study Part 2 | 17 | 20 |
| Participants | Part 2: Oral Aprepitant | Part 2: Intravenous Ondansetron |
|---|---|---|
| No Vomiting | 20 | 20 |
| 1 Vomiting Episode | 5 | 3 |
| 2 Vomiting Episodes | 0 | 1 |
| 3 Vomiting Episodes | 0 | 0 |
| >3 Vomiting Episodes | 0 | 1 |
Collected over Up to Day 21 post-surgery.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Oral Aprepitant | — | 3/46 (6.5%) | 14/46 (30.4%) |
| Part 2: Oral Aprepitant | — | 2/27 (7.4%) | 5/27 (18.5%) |
| Part 2: Intravenous Ondansetron | — | 0/25 (0%) | 4/25 (16%) |
| Event | Part 1: Oral Aprepitant | Part 2: Oral Aprepitant | Part 2: Intravenous Ondansetron |
|---|---|---|---|
| Incision Site InfectionInfections and infestations | 2/46 | 1/27 | 0/25 |
| PneumoniaInfections and infestations | 0/46 | 1/27 | 0/25 |
| Anastomotic ComplicationInjury, poisoning and procedural complications | 1/46 | 0/27 | 0/25 |
| Event | Part 1: Oral Aprepitant | Part 2: Oral Aprepitant | Part 2: Intravenous Ondansetron |
|---|---|---|---|
| VomitingGastrointestinal disorders | 10/46 | 1/27 | 0/25 |
| NauseaGastrointestinal disorders | 4/46 | 0/27 | 0/25 |
| Chest PainGeneral disorders | 0/46 | 2/27 | 2/25 |
| PyrexiaGeneral disorders | 3/46 | 0/27 | 2/25 |
| Abdominal PainGastrointestinal disorders | 3/46 | 2/27 | 0/25 |
| Age, Customized(Participants) | Part 1: Oral Aprepitant | Part 2: Oral Aprepitant | Part 2: Intravenous Ondansetron | Total |
|---|---|---|---|---|
| 0.5 to <2 years | 14 | 8 | 5 | 27 |
| 2 to <6 years | 11 | 7 | 7 | 25 |
| 6 to <12 years | 11 | 5 | 6 | 22 |
| 12 to 17 years | 10 | 7 | 7 | 24 |
| Sex: Female, Male(Participants) | Part 1: Oral Aprepitant | Part 2: Oral Aprepitant | Part 2: Intravenous Ondansetron | Total |
|---|---|---|---|---|
| Female | 13 | 6 | 12 | 31 |
| Male | 33 | 21 | 13 | 67 |
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Jan 2009 to primary completion in Mar 2013, 49 months.
Results were first posted in Feb 2014, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aprepitant
Postoperative Nausea and Vomiting →